Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze TARS Tarsus Pharmaceuticals, Inc.. Please read: https://finlab.finance/en/setup?stock=TARS

No install, write strategies with AI

TARS

Tarsus Pharmaceuticals, Inc. Healthcare As of 2026-07-16 Updated daily after market close

quality needs a look, discounted valuation, no active signal today.

This page refreshes daily after the close. Add Tarsus Pharmaceuticals, Inc. to your watchlist to track signal changes on your next visit.
Valuation 48Quality 28Growth 62Momentum 49Risk / liquidity 65

Is Tarsus Pharmaceuticals, Inc. a buy? Fundamentals and valuation first

  • Quality is weaker than peers. Operating margin is only around the 26th percentile. TTM ROE is about -13.8%.

  • Valuation is cheaper than most peers. TTM P/E is in the 6th percentile, lower than most liquid US common stocks.

  • Recent volatility is moderate. 60-day annualized volatility is near the 54th percentile. Average 20-day dollar volume is about $86.3M.

Historical evidence

Market-wide momentum baseline

Across 96,215 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.34%, a 58.2% positive-return rate, and +2.98 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

8 times historically; 60-day forward avg +8.23%, win rate 50%, beating the market by +6.72 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

13 times historically; 60-day forward avg +0.49%, win rate 30.8%, beating the market by -2.5 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

5 times historically; 60-day forward avg +16.24%, win rate 80%, beating the market by +13.12 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

15 times historically; 60-day forward avg +11.7%, win rate 57.1%, beating the market by +6.86 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.